系统性硬化症相关的间歇性肺病中的宁达尼布:关于耐受性和停止治疗的现实世界队列研究
Punchalee Kaenmuang1, Nina R Goldman2, Arthihai Srirangan3
1Interstitial Lung Disease Unit, Royal Brompton Hospital, Guy's and St Thomas' National Health Service Foundation Trust, London; Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, Imperial College London, UK; and Respiratory and Respiratory Critical Care Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand. punchalee.k@psu.ac.th.
在系统性硬化症相关的间歇性肺病 (SSc-ILD) 患者中,特别是老年人和低BMI患者中,中断宁达尼布治疗是常见的. 密切监测和支持性护理对于管理副作用和保持治疗连续性至关重要.
科学领域:
- 肺部病理学 肺部病理学
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 丁丁达尼布已被批准用于治疗系统性硬化症相关的间歇性肺病 (SSc-ILD).
- 耐受性和治疗中断是 SSc-ILD 接受 nintedanib.患者的潜在问题.
研究的目的:
- 为了评估宁泰达尼布在SSc-ILD患者的耐受性.
- 确定与治疗中断和永久停药相关的因素.
主要方法:
- 一项涉及63名SSc-ILD患者的多中心研究,这些患者接受了nintedanib治疗.
- 使用后勤和考克斯回归分析治疗中断,中断原因和第一次中断的时间.
- 在开始使用宁泰丹尼布之前和之后的体重变化比较.
主要成果:
- 51%的患者经历了忍丹尼布的中断,最常见的原因是腹,恶心/吐和体重减轻.
- 高龄和体重指数 (BMI) <18.5 kg/m2独立地与治疗中断有关.
- 永久停药发生在20.6%的患者中,没有发现任何显著的预测因素.
- 与治疗前的时期相比,在开始使用宁泰丹尼布后观察到显著的体重减轻.
结论:
- 在SSc-ILD患者中,副作用经常导致宁泰达尼布治疗中断.
- 高龄和较低的BMI预测治疗中断,强调需要个性化管理.
- 大多数患者可以恢复忍丹尼布,这强调了支持性护理对副作用管理和治疗坚持的重要性.
更多相关视频
11:31Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer
Published on: May 20, 2016
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
COPD: Management Using Bronchodilators and Corticosteroids
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Bioavailability Study Design: Healthy Subjects Versus Patients
Therapeutic Drug Monitoring: Affecting Factors
